India Biosimilars Market Size & Share 2026-2035

India Biosimilars Market Size

The India biosimilars market is valued at USD 1.5 billion in 2025 and is projected to rise from USD 1.9 billion in 2026 to USD 8.1 billion by 2035, representing a 17.8% CAGR over 2026-2035.

Demand is anchored in disease categories where long-duration therapy and high biologic costs create persistent affordability pressure. India had an estimated 89.83 million adults aged 20-79 living with diabetes in 2024, equivalent to a 10.5% prevalence rate. ^{[1]Diabetes Asia Journal, IDF Diabetes Atlas 2025 India figures, diabetesasia.org} Diabetes is only one part of the addressable burden: oncology, hematology, autoimmune disease, and growth hormone deficiency also rely on biologic therapies whose cost and treatment duration can limit continuity of care.

India's biosimilar base has expanded alongside its regulatory and manufacturing ecosystem. The country had approved 135 biosimilars by January 2025. ^{[2]BioSpectrum India, India biosimilar approvals, biospectrumindia.com} The Central Drugs Standard Control Organization (CDSCO) oversees biological-product regulation under the Similar Biologics framework. ^{[3]Central Drugs Standard Control Organization, Biologicals Division, cdsco.gov.in} This combination of a sizable domestic treatment need, accumulated development capability, and an established approval pathway has created a market in which biosimilars can serve both domestic access requirements and international commercialization strategies.

Affordability remains commercially important because the cost of care is often borne directly by households. Academic estimates based on household-expenditure survey data have found that out-of-pocket health spending can push roughly 31 million to 39 million Indians below the poverty line annually, although these estimates should not be interpreted as a current annual count for biosimilar-treated patients. ^{[4]Journal of Family Medicine and Primary Care, OOP health expenditure and poverty in India, ncbi.nlm.nih.gov} For providers and manufacturers, the implication is that biosimilar uptake depends not only on approval and list price, but also on whether products can be placed within hospital protocols, public programs, and reliable distribution channels.

The decisive constraint is not simply the number of approved molecules. With 135 approvals already recorded by early 2025, commercial advantage increasingly shifts toward evidence generation, physician confidence, institutional procurement, cold-chain execution, and the ability to keep therapy available after initiation. Companies that treat registration as the end of the process may struggle to convert approvals into recurring use; those that align manufacturing scale with hospital access and payer pathways are better positioned to capture the next phase of demand.

Key Drivers

Rising chronic disease burden. India's disease burden creates sustained demand for affordable biologic treatment across multiple therapeutic areas. The estimated 89.83 million adults with diabetes in 2024 supports demand for insulin biosimilars, while oncology and hematology treatment pathways create demand for monoclonal antibodies, erythropoietins, and colony-stimulating factors. The commercial significance lies in treatment persistence: chronic and recurrent conditions require reliable access over time, making supply continuity and institutional availability as important as the initial prescription decision.

Strong domestic manufacturing capabilities. India's accumulated biologics capabilities support a larger biosimilar opportunity than simple import substitution. The 135 biosimilars approved by January 2025 indicate that domestic manufacturers have built experience across development, regulatory submission, analytical comparability, and commercialization. These capabilities can reduce dependence on imported reference products and finished therapies, while also allowing Indian firms to use domestic scale as a base for regulated-market expansion.

The advantage remains conditional. Biosimilar manufacturing requires consistent cell-line performance, process control, analytical characterization, and pharmacovigilance. Manufacturing scale therefore creates value only when it is paired with quality systems capable of meeting both Indian and export-market requirements.

Government support and policy initiatives. Public policy is increasingly directed toward strengthening the biologics ecosystem. The Union Budget 2026-27 announced Biopharma SHAKTI, allocating Rs. 10,000 crore, approximately USD 1.2 billion, over five years to support an end-to-end domestic biologics and biosimilars ecosystem and reduce import dependence. ^{[5]Press Information Bureau, Government of India, Biopharma SHAKTI, pib.gov.in} The program can improve the economics of domestic development by directing attention to research infrastructure, manufacturing capability, and commercialization capacity rather than treating biosimilars solely as finished pharmaceutical products.

The regulatory setting is also evolving. CDSCO administers biological-product approvals and issued the 2016 Guidelines on Similar Biologics; it published a consultation notice for revised similar-biologics guidelines in May 2025. Regulatory modernization can improve clarity for developers, but it also raises the importance of keeping comparability, clinical, and quality dossiers aligned with current expectations.

Biosimilar access could broaden further if public treatment pathways incorporate these products more consistently. Analysis of Ayushman Bharat has identified integration of biosimilars into treatment protocols as a route to improve access to lower-cost biologic therapies. ^{[6]Business Standard, Biosimilars and India's healthcare costs, business-standard.com} The opportunity is practical rather than automatic: inclusion in a program does not ensure uptake unless hospitals can procure, store, prescribe, and monitor the therapy.

High cost of originator biologics. The economic case for biosimilars is strongest where originator biologics are difficult for households and hospitals to fund at scale. Out-of-pocket expenditure has historically created severe financial stress for Indian households, making lower-cost alternatives relevant even when a medicine is clinically available. This pressure is particularly material in oncology and autoimmune disease, where therapy may require repeated administration, supportive treatment, or long-term monitoring.

Price alone, however, does not guarantee substitution. Prescribers need confidence in the product's quality and therapeutic comparability, while hospitals need procurement certainty and distributors need workable inventory economics. Price competition that erodes the ability to maintain quality, service, and pharmacovigilance can ultimately weaken adoption rather than accelerate it.

Key Restraints

Limited penetration beyond urban centers. Biosimilar availability is uneven because the care infrastructure required for diagnosis, initiation, monitoring, infusion, and adverse-event management remains concentrated in larger urban health systems. Hospital pharmacies account for 53.15% of market revenue in 2025, indicating that institutional channels remain central to treatment access. This channel concentration can support high-complexity care, but it also exposes uptake to geographic gaps in specialist availability and referral networks.

Expansion into semi-urban and rural markets is therefore not a standard distribution exercise. It requires coordination among physicians, diagnostic facilities, hospitals, specialty distributors, and patient-support mechanisms. Products with simpler administration and established treatment pathways may diffuse faster than infusion-dependent therapies that depend on tertiary-care infrastructure.

Complex development and regulatory requirements. Biosimilars cannot be developed as conventional generics. Developers must establish a scientifically credible similarity package across analytical characterization, quality attributes, non-clinical evidence where required, clinical evidence, and post-marketing safety commitments. CDSCO's continued work on the Similar Biologics framework reinforces the need for regulatory planning that anticipates evolving evidence expectations.

These requirements create a two-sided market effect. They protect patients and preserve confidence in approved products, but they also favor companies with specialized development, manufacturing, and regulatory resources. Smaller firms may have difficulty absorbing the cost of comparability programs, maintaining batch consistency, and building pharmacovigilance systems, particularly when pricing pressure limits the return available from a single molecule.

Regulatory rigor compounds this divide. A more mature approval framework improves trust and discourages low-quality competition, yet it raises the capital and technical threshold for developers. The likely outcome is a more selective competitive environment in which firms with robust manufacturing control, regulatory capability, and channel partnerships gain share, while approval counts alone become a weaker indicator of commercial success.

India Biosimilars Market Segment Analysis

Product

Recombinant glycosylated proteins account for 69.43% of the market in 2025 and are expected to reach approximately USD 5.65 billion by 2035. This category includes monoclonal antibodies such as infliximab, rituximab, adalimumab, trastuzumab, and bevacizumab; erythropoietins; follitropins; and fusion proteins. Its scale reflects the high value and clinical complexity of biologics used in oncology, autoimmune disease, and specialty care. Manufacturing and analytical demands are substantial because glycosylation patterns and other quality attributes can influence product performance, making scale-up and consistency central competitive variables.

Recombinant non-glycosylated proteins hold 23.25% of the 2025 market and are forecast to grow at an 18.07% CAGR through 2035, the fastest rate among product categories. Human growth hormone, G-CSF/filgrastim, insulin, and interferon alfa/beta products can benefit from established treatment pathways and expanding chronic-disease demand. The category's faster growth suggests that products with broad patient populations and repeat-use requirements may continue to widen access, particularly where physician familiarity is already established.

Other products represent 7.32% of the market in 2025. Their smaller base provides room for differentiated offerings, but commercial viability will depend on whether development costs can be justified by addressable patient volume and credible channel access.

Application

Hematology is the largest application, accounting for 31.21% of the market in 2025 and projected to reach approximately USD 2.54 billion by 2035. Neutropenia and anemia management benefit from hospital-based treatment protocols, where formulary decisions can drive concentrated volume. This makes the segment attractive for suppliers able to secure institutional procurement while ensuring uninterrupted availability.

Autoimmune disease represents 24.31% of the market and is projected to expand at an 18.14% CAGR. Rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, psoriasis, and related conditions require sustained treatment, making adherence, patient education, and specialist acceptance important determinants of biosimilar conversion.

Oncology accounts for 20.43% of 2025 revenue and is forecast to grow at an 18.44% CAGR, the highest among applications. The category includes lung, brain, breast, cervical, colorectal, leukemia, and other cancers. Oncology biosimilars must compete within clinically sensitive treatment pathways, where procurement savings are meaningful but physician confidence, safety monitoring, and continuity of supply remain essential.

Diabetes contributes 12.54% of the market, followed by growth hormone deficiency at 5.74%, ophthalmology at 3.34%, and other applications at 2.42%. Diabetes offers a large potential treatment population, but commercialization depends on reaching patients beyond specialist urban centers and balancing affordability with dependable long-term supply.

Manufacturing Type

In-house manufacturing represents 62.95% of market revenue in 2025, equivalent to approximately USD 968 million, and is projected to grow at a 17.72% CAGR. Vertical control can help developers protect process knowledge, coordinate quality management, and preserve supply continuity. It also requires sustained investment in facilities, validation, skilled personnel, and compliance systems.

Contract research and manufacturing services account for 37.05% of the market and are forecast to grow slightly faster, at 17.97%. Outsourced models can lower the capital barrier for pipeline expansion and allow manufacturers to access specialized capabilities, but they increase dependence on partner capacity, technology transfer discipline, and quality oversight. Contracting is therefore most valuable when it supplements, rather than substitutes for, a clear product and regulatory strategy.

Technology

Recombinant DNA technology accounts for 67.32% of market revenue in 2025 and is expected to grow at a 17.76% CAGR through 2035. Its predominance reflects its role as the development foundation for many biosimilar proteins. Competitive differentiation within this technology lies less in basic platform access than in the ability to optimize expression, purification, analytical comparability, and scalable process economics.

Mammalian cell culture systems account for 23.96% of the market and are projected to expand at an 18.07% CAGR. The category is particularly relevant to more complex glycosylated proteins and monoclonal antibodies, where biologic expression and product-characterization demands can be high. Other technologies represent 8.72% of the market, providing a smaller but potentially important base for product-specific process innovation.

Distribution Channel

Hospital pharmacies hold 53.15% of 2025 revenue and are projected to grow at a 17.77% CAGR. Their leading position reflects the role of hospitals in oncology, hematology, infusion-based care, treatment initiation, and physician-supervised prescribing. Institutional procurement can accelerate adoption when a biosimilar is embedded in a protocol, but it can also concentrate bargaining power and intensify price competition.

Specialty pharmacies account for 33.48% of the market and are expected to grow at an 18.03% CAGR. They are important for therapies requiring storage control, patient education, refill coordination, and ongoing adherence support. Other distribution channels represent 13.37%; their role will depend on whether treatment complexity, local provider capacity, and reimbursement arrangements allow care to move outside hospital-centric settings.

The most consequential intersection is between product complexity and channel design. A monoclonal antibody program can create significant revenue but requires high technical control and hospital integration; a non-glycosylated therapy can scale more broadly but may face greater price sensitivity and distribution demands. Manufacturers that match product selection to their manufacturing architecture and channel capabilities are more likely to generate durable volume than firms pursuing molecule breadth without a defined access model.

India Biosimilars Market Regional Analysis

India's biosimilars market is national in regulatory scope but uneven in practical access. Metropolitan and tertiary-care hubs are likely to remain the primary centers for high-complexity biologic use because they concentrate oncology centers, specialty physicians, infusion facilities, diagnostics, and hospital procurement systems. This concentration supports early adoption of monoclonal antibodies and hospital-administered therapies, while also creating a higher bar for expansion into less specialized markets.

Semi-urban growth depends on whether biosimilars can be integrated into referral networks and supported by local diagnostics, physician training, and reliable cold-chain distribution. The commercial challenge is particularly acute for therapies requiring regular monitoring or administration within an institutional setting. Suppliers may need different operating models across states and cities rather than a single national launch approach.

Rural access remains constrained by specialist availability, travel distance to tertiary centers, and the financial burden associated with repeated treatment. The high share of hospital pharmacies in market revenue indicates that biologic access remains tied to institutional care. Broader diffusion will depend on whether specialty pharmacy services, patient-support systems, public treatment pathways, and appropriately trained local providers can reduce the distance between approval and treatment initiation.

State-level variation should be assessed through healthcare infrastructure, procurement systems, specialist density, and public-program implementation rather than assumed from population alone. Large population centers may offer substantial demand, but the more immediate commercial opportunity is often found where hospital networks can standardize prescribing and sustain supply after conversion from an originator therapy.

The next phase of growth requires selective decentralization rather than indiscriminate geographic expansion. Companies must identify locations where specialty-care infrastructure is sufficient to support treatment continuity, then adapt medical engagement, inventory planning, and patient support to local conditions. The strongest regional strategies will extend the reach of proven therapies without compromising pharmacovigilance, cold-chain integrity, or clinician confidence.

India Biosimilars Market Share & Competitive Landscape

The five leading companies - Biocon Biologics, Intas Pharmaceuticals, Dr. Reddy's Laboratories, Zydus Lifesciences, and Reliance Life Sciences - collectively account for approximately 49% of the India biosimilars market in 2025. This concentration indicates meaningful scale advantages, but the remaining market remains open to companies that can differentiate through product selection, manufacturing execution, institutional access, or targeted therapeutic specialization.Biocon Biologics illustrates the value of portfolio breadth across therapeutic settings. Its Ogivri trastuzumab biosimilar is marketed across approximately 120 countries. ^{[7]Biocon, Biocon Biologics global biosimilars integration, biocon.com} SEMGLEE insulin glargine-yfgn is identified by Biocon Biologics as the first interchangeable biosimilar approved by the U.S. Food and Drug Administration. ^{[8]Biocon Biologics, Insulin glargine portfolio, bioconbiologics.com} These assets demonstrate how Indian biosimilar manufacturers can use global regulatory experience and multi-market commercialization to reinforce credibility in domestic specialty-care markets.

Intas Pharmaceuticals has established a position in supportive oncology care through Accord Healthcare. Accofil, a filgrastim biosimilar to Neupogen, was launched in Europe through Accord. ^{[9]PR Newswire, Intas Pharmaceuticals Accofil EU launch, prnewswire.com} European Medicines Agency product information identifies its use in reducing neutropenia duration and febrile-neutropenia incidence in patients receiving cytotoxic chemotherapy. ^{[10]European Medicines Agency, Accofil EPAR product information, ema.europa.eu} Such experience is commercially relevant in India because hospital-based oncology care rewards suppliers that can provide consistent availability, clinical familiarity, and institutionally usable product support.
Competitive intensity is likely to rise as more developers pursue molecules with large addressable markets or approaching biologic patent expiries. The durable advantage will not come from approval volume alone. Companies need development programs that can meet evolving regulatory requirements, manufacturing systems that protect comparability at scale, and access strategies that convert hospital procurement into sustained treatment use.

Recent Industry Developments

In April 2025, Accord BioPharma, Intas Pharmaceuticals' U.S. specialty division, completed the acquisition of the UDENYCA pegfilgrastim-cbqv franchise from Coherus BioSciences. The transaction expanded Intas' global oncology-supportive-care platform and strengthened its pegfilgrastim presence.

In June 2025, Dr. Reddy's Laboratories and Alvotech entered a collaboration and license agreement to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda, pembrolizumab, for global markets. The partnership signals a move toward complex, high-value immuno-oncology biosimilars, where development risk and commercialization requirements can favor shared capability models.

In December 2025, Zydus Lifesciences launched Zyrifa, a biosimilar denosumab 120 mg subcutaneous injection, in India for prevention of skeletal-related complications in cancer patients. The company listed an MRP of Rs. 12,495, positioning the launch as an access-oriented addition to oncology supportive care.